In the absence of lymph-node involvement, adjuvant chemotherapy is not fully recommended for HER2-overexpressing breast cancers of less than 5 mm (pT1mi and pT1a) [10, 11]. The gene discussed is ERBB2; the disease is breast carcinoma.